The pharmacokinetics and safety of ritonavir-boosted indinavir 600/100mg bid combined with NRTIs [nucleoside reverse transcriptase inhibitors] in ARV [antiretroviral therapy] naive HIV/TB [HIV/tuberculosis] co-infected patients receiving rifampicin containing anti-tuberculosis therapy

Trial Profile

The pharmacokinetics and safety of ritonavir-boosted indinavir 600/100mg bid combined with NRTIs [nucleoside reverse transcriptase inhibitors] in ARV [antiretroviral therapy] naive HIV/TB [HIV/tuberculosis] co-infected patients receiving rifampicin containing anti-tuberculosis therapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2010

At a glance

  • Drugs Indinavir (Primary) ; Ritonavir (Primary) ; Antituberculars; Nucleoside reverse transcriptase inhibitors; Rifampicin
  • Indications HIV infections; Tuberculosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Jun 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 04 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Planned end date changed from 1 Dec 2007 to 1 Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top